Molecular correlates of platinum response in human high-grade serous ovarian cancer patient-derived xenografts-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Molecular correlates of platinum response in human high-grade serous ovarian cancer patient-derived xenografts

Published:2014-01-24 Issue:3 Volume:8 Page:656-668
ISSN:1574-7891
Container-title:Molecular Oncology
language:en
Short-container-title:

Author:

Topp Monique D.,Hartley Lynne,Cook Michele,Heong Valerie,Boehm Emma,McShane Lauren,Pyman Jan,McNally Orla,Ananda Sumitra,Harrell Marisol,Etemadmoghadam Dariush,Galletta Laura,Alsop Kathryn,Mitchell Gillian,Fox Stephen B.,Kerr Jeffrey B.,Hutt Karla J.,Kaufmann Scott H.,Swisher Elizabeth M.,Bowtell David D.,Wakefield Matthew J.,Scott Clare L.,

Funder

National Health and Medical Research Council

Cancer Council Victoria

Victorian Cancer Agency

CRC for Cancer Therapeutics

National Institute of Health

Wendy Feuer Ovarian Cancer Research Fund (EMS)

Publisher

Wiley

Subject

Cancer Research,Genetics,Molecular Medicine,General Medicine,Oncology

Reference33 articles.

1. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary;Ahmed;J. Pathol.,2010

2. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group;Alsop;J. Clin. Oncol.,2012

3. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial;Audeh;Lancet,2010

4. Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor;Barber;J. Pathol.,2013

5. The landscape of somatic copy-number alteration across human cancers;Beroukhim;Nature,2010

Cited by 120 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CHK1 inhibitor SRA737 is active in PARP inhibitor resistant and CCNE1 amplified ovarian cancer;iScience;2024-07

2. Epigenetic editing of BRCA1 promoter increases cisplatin and olaparib sensitivity of ovarian cancer cells;Epigenetics;2024-05-26

3. Creation and Validation of Patient-Derived Cancer Model Using Peritoneal and Pleural Effusion in Patients with Advanced Ovarian Cancer: An Early Experience;Journal of Clinical Medicine;2024-05-06

4. Nanoparticle-Encapsulated Epirubicin Efficacy in the Inhibition of Growth of Orthotopic Ovarian Patient-Derived Xenograft in Immunocompromised Mice;International Journal of Molecular Sciences;2024-01-04

5. Current and future perspectives of xenograft models of human ovarian cancer;Peritoneal Tumor Microenvironment of Cancers on Cancer Hallmarks;2024

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3